Retatrutide: The Triple-Agonist Weight Loss Peptide

TL;DR: Retatrutide (LY3437943) is Eli Lilly's investigational triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. In Phase 2 clinical trials published in the New England Journal of Medicine (Jastreboff et al., 2023), the 12mg dose produced 24.2% mean body weight loss over 48 weeks — the largest weight reduction reported for any anti-obesity medication at the time of publication. Retatrutide is currently in Phase 3 trials and is not yet FDA-approved.

What is Retatrutide?

Retatrutide is a single-molecule peptide agonist that activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. Developed by Eli Lilly under the research designation LY3437943, it represents the first triple-agonist to reach advanced clinical trials for obesity and type 2 diabetes.

The drug belongs to an evolving class of multi-receptor metabolic peptides. Semaglutide (Ozempic/Wegovy) targets only GLP-1. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP. Retatrutide adds glucagon receptor activation as a third mechanism, which introduces direct effects on energy expenditure and hepatic fat metabolism that the dual-agonist approach does not provide.

Retatrutide is administered as a once-weekly subcutaneous injection and is designed as a long-acting peptide with a pharmacokinetic profile supporting weekly dosing. It is not yet approved by the FDA or any other regulatory agency and remains available only through clinical trials.

How It Works

Retatrutide's triple-agonist mechanism engages three distinct receptor pathways, each contributing different metabolic effects.

GLP-1 Receptor Agonism

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut in response to food intake. GLP-1 receptor activation produces several effects relevant to weight management and metabolic health:

• Appetite suppression. GLP-1 acts on hypothalamic and brainstem centers to reduce hunger and increase satiety. This is the primary mechanism driving weight loss with semaglutide and other GLP-1 agonists.
• Slowed gastric emptying. GLP-1 delays the rate at which food leaves the stomach, prolonging feelings of fullness after meals. This also contributes to the gastrointestinal side effects (nausea, vomiting) seen during dose escalation.
• Glucose-dependent insulin secretion. GLP-1 stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, reducing the risk of hypoglycemia compared to older diabetes medications.
• Glucagon suppression. Paradoxically, while retatrutide also directly activates glucagon receptors, GLP-1-mediated glucagon suppression is glucose-dependent and helps maintain glycemic control.

GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. Its role in obesity pharmacology was considered controversial until tirzepatide's clinical success demonstrated that GIP agonism enhances weight loss outcomes beyond GLP-1 alone.

• Enhanced insulin sensitivity. GIP receptor activation improves insulin signaling in adipose tissue and may promote more metabolically favorable fat distribution.
• Central appetite effects. GIP receptors are expressed in the brain, and emerging evidence suggests GIP agonism contributes to appetite regulation through pathways distinct from GLP-1 (Samms et al., 2022).
• Complementary incretin effect. GIP and GLP-1 together account for approximately 50-70% of postprandial insulin secretion. Activating both receptors restores a more complete incretin response than either alone.
• Potential beta cell preservation. Animal studies suggest GIP agonism may support pancreatic beta cell survival and function, though long-term human data is still being collected.

Glucagon Receptor Agonism

The addition of glucagon receptor activation is what distinguishes retatrutide from all approved obesity medications. Glucagon, produced by pancreatic alpha cells, has traditionally been viewed only as a counter-regulatory hormone that raises blood sugar. However, its metabolic effects extend well beyond glucose regulation:

• Increased energy expenditure. Glucagon receptor activation increases resting energy expenditure (thermogenesis), meaning the body burns more calories at rest. This addresses a limitation of GLP-1-only drugs, which reduce weight primarily by decreasing caloric intake without meaningfully increasing metabolic rate (Habegger et al., 2010).
• Hepatic fat reduction. Glucagon promotes hepatic lipid oxidation — the breakdown of fat stored in the liver. This is particularly relevant for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH), a condition affecting many individuals with obesity. Phase 2 data showed retatrutide produced dramatic reductions in liver fat content.
• Lipolysis. Glucagon stimulates the breakdown of stored fat (triglycerides) in adipose tissue, mobilizing fatty acids for energy use.
• Amino acid metabolism. Glucagon influences amino acid catabolism, which may contribute to the body composition changes observed with retatrutide.

The concern with glucagon agonism is its hyperglycemic effect — glucagon raises blood sugar by stimulating hepatic glucose production. In retatrutide, this effect is counterbalanced by the simultaneous GLP-1 and GIP receptor activation, which enhance insulin secretion and suppress inappropriate glucagon signaling in a glucose-dependent manner. Clinical trial data confirms that retatrutide improves glycemic control despite the glucagon component.

Clinical Trial Results

Phase 2 Trial (Jastreboff et al., 2023)

The pivotal Phase 2 trial, published in The New England Journal of Medicine in June 2023, was a 48-week, randomized, double-blind, placebo-controlled study in 338 adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity.

Weight loss results at 48 weeks by dose group:

• Placebo: -2.1% body weight
• 1mg: -8.7% body weight
• 4mg (escalated from 2mg): -17.1% body weight
• 8mg (escalated from 2mg): -22.8% body weight
• 12mg (escalated from 2mg): -24.2% body weight

The 24.2% mean body weight loss in the 12mg group represented the largest weight reduction achieved by any anti-obesity medication in a clinical trial at the time of publication. For context, semaglutide 2.4mg (Wegovy) produced approximately 15-17% weight loss in the STEP trials, and tirzepatide 15mg (Zepbound) produced approximately 22.5% in the SURMOUNT-1 trial.

Additional findings:

• Liver fat reduction. In a sub-study of participants with MASH, retatrutide produced mean relative reductions in liver fat content of up to 82% at 48 weeks. More than 80% of participants on the 8mg and 12mg doses achieved normalization of liver fat (defined as less than 5% liver fat content).
• Metabolic improvements. Significant reductions in HbA1c, fasting glucose, triglycerides, and blood pressure were observed across dose groups.
• Dose-dependent response. Weight loss increased with dose, and the weight loss curves had not fully plateaued at 48 weeks for the higher doses, suggesting continued weight loss may occur with longer treatment.
• Waist circumference. Mean reduction of approximately 20cm (nearly 8 inches) in the 12mg group.

Phase 2 Type 2 Diabetes Trial

A separate Phase 2 trial in adults with type 2 diabetes (Rosenstock et al., 2023) showed that retatrutide produced HbA1c reductions of up to 2.02 percentage points and weight loss of up to 16.9% at 36 weeks. These results compare favorably to tirzepatide in the same population.

Phase 3 Trials

As of 2026, Eli Lilly is conducting Phase 3 clinical trials for retatrutide in obesity and MASH. These larger, longer trials will provide the data needed for regulatory submissions. Key ongoing Phase 3 studies include:

• TRIUMPH program: Multiple Phase 3 trials evaluating retatrutide for obesity/overweight
• MASH trials: Evaluating retatrutide for metabolic liver disease

Benefits

Based on published clinical trial data:

• Substantial weight loss. Up to 24.2% body weight reduction at 48 weeks in Phase 2, with the weight loss curve still trending downward, suggesting greater losses with longer treatment.
• Superior to existing medications. The 12mg dose produced meaningfully greater weight loss than reported for semaglutide or tirzepatide in their respective trials, though direct head-to-head comparison studies have not been completed.
• Liver fat reduction. Dramatic reductions in hepatic steatosis, with potential to become a treatment for MASH — a condition with limited approved therapies.
• Metabolic health improvement. Comprehensive improvements in glycemic control, lipid profiles, blood pressure, and inflammatory markers across dose groups.
• Increased energy expenditure. Unlike pure GLP-1 agonists that work only by reducing intake, retatrutide's glucagon component actively increases calorie burning, potentially helping preserve metabolic rate during weight loss.
• Once-weekly dosing. Convenient administration schedule consistent with other modern injectable obesity medications.
• Body composition. While detailed body composition data from Phase 3 is pending, the glucagon component's lipolytic effects suggest retatrutide may produce a more favorable fat-to-lean mass loss ratio compared to appetite-suppression-only approaches, though this remains to be confirmed.

Dosing

Important: Retatrutide is an investigational drug not yet approved for clinical use. It is only available through clinical trials. The following dosing information is derived from published Phase 2 clinical trial protocols.

Phase 2 Trial Protocol (Jastreboff et al., 2023)

All higher-dose groups used a gradual escalation protocol to minimize gastrointestinal side effects:

12mg target dose escalation schedule: - Weeks 1-4: 2mg once weekly - Weeks 5-8: 4mg once weekly - Weeks 9-12: 8mg once weekly - Weeks 13-48: 12mg once weekly

8mg target dose escalation schedule: - Weeks 1-4: 2mg once weekly - Weeks 5-8: 4mg once weekly - Weeks 9-48: 8mg once weekly

4mg target dose escalation schedule: - Weeks 1-4: 2mg once weekly - Weeks 5-48: 4mg once weekly

Administration

• Route: Subcutaneous injection, once weekly
• Injection sites: Abdomen, thigh, or upper arm, with site rotation
• Timing: Same day each week, at any time of day, with or without food

Key Dosing Principles

• Gradual escalation is essential. The dose titration schedule exists to allow gastrointestinal tolerance to develop. Rapid dose escalation significantly increases the incidence and severity of nausea, vomiting, and diarrhea.
• Dose-dependent efficacy. Weight loss was clearly dose-dependent in Phase 2, with the 12mg dose producing substantially greater effects than 4mg. However, even the 4mg dose produced clinically meaningful weight loss (17.1%).
• No plateau at 48 weeks. Weight loss curves for the 8mg and 12mg groups had not plateaued at the end of the 48-week study, suggesting optimal treatment duration may be longer.

Timeline: What to Expect

The following timeline is based on Phase 2 clinical trial data (Jastreboff et al., 2023):

Weeks 1-4 (2mg escalation phase): Appetite reduction is typically the first noticeable effect. Most participants experience decreased hunger and earlier satiety. Weight loss begins, though modestly at the starting dose. GI side effects (nausea, decreased appetite) may occur as the body adjusts.

Weeks 5-12 (dose escalation): As the dose increases through 4mg and 8mg, appetite suppression becomes more pronounced. Weight loss accelerates. GI side effects may recur briefly with each dose increase but typically resolve within 1-2 weeks. By the end of this phase, many participants had already lost 10-15% of body weight.

Weeks 12-24 (maintenance dose): Rapid weight loss continues at the target maintenance dose. By 24 weeks, the 12mg group had achieved approximately 17-19% mean body weight loss, already exceeding the maximum effect of semaglutide. Metabolic markers (blood sugar, lipids, blood pressure) show continued improvement.

Weeks 24-48 (continued treatment): Weight loss continues but at a gradually decreasing rate. The 12mg group reached 24.2% mean loss at 48 weeks. Liver fat reductions become dramatic during this period. GI side effects have typically resolved by this point for most patients.

Beyond 48 weeks: Phase 3 data will clarify long-term trajectories. Based on the non-plateaued curves at 48 weeks, additional weight loss is expected with continued treatment. As with all GLP-1 class medications, some weight regain is expected upon discontinuation.

Side Effects & Safety

Gastrointestinal Effects

GI side effects are the most common adverse events with retatrutide, consistent with other GLP-1 receptor agonists:

• Nausea: Reported by 25-50% of participants across dose groups (compared to 9% placebo). Most common during dose escalation periods and typically transient.
• Diarrhea: Reported by 20-35% at higher doses. Usually mild to moderate in severity.
• Vomiting: Reported by 10-20% at higher doses. Most frequent during the first 2-4 weeks of each dose increase.
• Constipation: Reported by 10-15%. Related to slowed gastric emptying from GLP-1 activity.
• Decreased appetite: While technically a therapeutic effect, some participants experienced appetite reduction they considered excessive, particularly at higher doses.

The gradual dose escalation protocol significantly reduces the incidence and severity of GI side effects. Most participants who experienced GI symptoms found they resolved within the first few weeks at each dose level.

Discontinuation Rates

In the Phase 2 trial, treatment discontinuation due to adverse events was 6% in the 12mg group, compared to 4% in the placebo group. This relatively low discontinuation rate suggests the side effect profile is manageable for most patients.

Other Reported Side Effects

• Injection site reactions. Mild erythema or pruritus at the injection site, typically transient.
• Heart rate increase. Small mean increases in resting heart rate (2-4 beats per minute) were observed, consistent with other GLP-1 agonists.
• Hypoglycemia. Uncommon in non-diabetic participants. In the type 2 diabetes trial, hypoglycemia was more frequent when combined with sulfonylurea or insulin.

Safety Considerations

• No pancreatitis signal. No cases of pancreatitis were reported in Phase 2. However, all GLP-1 class drugs carry a theoretical pancreatitis risk, and long-term surveillance is needed.
• Thyroid concern. GLP-1 agonists carry a boxed warning regarding medullary thyroid carcinoma (MTC) risk based on rodent studies. This is a class-wide precaution. Retatrutide is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Gallbladder events. Rapid weight loss from any cause increases the risk of cholelithiasis (gallstones). This is a general risk of significant weight loss, not specific to retatrutide.
• Muscle mass loss. Like all obesity medications that produce large weight reductions, some loss of lean mass accompanies fat loss. Resistance training and adequate protein intake are recommended to preserve muscle mass. Whether retatrutide's glucagon component affects the fat-to-lean loss ratio differently from pure GLP-1 agonists will be evaluated in Phase 3.
• Pregnancy. Retatrutide should not be used during pregnancy or in women planning to become pregnant. It should be discontinued at least 2 months before a planned pregnancy (based on its long half-life).
• Drug interactions. Slowed gastric emptying may affect the absorption of oral medications. Patients on medications with narrow therapeutic windows should be monitored closely.

Frequently Asked Questions

What is retatrutide? Retatrutide is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. It is being developed by Eli Lilly for weight management and has shown up to 24.2% body weight reduction in Phase 2 clinical trials.

How is retatrutide different from semaglutide? Semaglutide is a single GLP-1 receptor agonist, while retatrutide targets three receptors (GLP-1, GIP, and glucagon). The triple-agonist approach may produce greater weight loss and metabolic benefits than single-receptor drugs.

How much weight can you lose on retatrutide? In Eli Lilly's Phase 2 trial, participants on the highest dose (12mg) lost an average of 24.2% of their body weight over 48 weeks — approximately 58 pounds for a 240-pound individual.

What are the side effects of retatrutide? The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation, particularly during dose escalation. These typically diminish over time. Gradual dose titration helps minimize GI side effects.

Is retatrutide FDA approved? Retatrutide is not yet FDA approved. It is in Phase 3 clinical trials as of 2026. Eli Lilly is developing it under the name LY3437943.

Sources

1. Jastreboff, A.M., Kaplan, L.M., Frias, J.P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. The New England Journal of Medicine, 389(6), 514-526. DOI: 10.1056/NEJMoa2301972

2. Rosenstock, J., Frias, J.P., Jastreboff, A.M., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, Phase 2 trial conducted in the USA. The Lancet, 402(10401), 529-544. DOI: 10.1016/S0140-6736(23)01053-X

3. Samms, R.J., Coghlan, M.P., & Sloop, K.W. (2020). How may GIP enhance the therapeutic efficacy of GLP-1? Trends in Endocrinology & Metabolism, 31(6), 410-421. DOI: 10.1016/j.tem.2020.02.006

4. Habegger, K.M., Heppner, K.M., Geary, N., et al. (2010). The metabolic actions of glucagon revisited. Nature Reviews Endocrinology, 6(12), 689-697. DOI: 10.1038/nrendo.2010.187

5. Coskun, T., Urva, S., Roell, W.C., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247. DOI: 10.1016/j.cmet.2022.07.013

6. Sanyal, A.J., Kaplan, L.M., Frias, J.P., et al. (2023). Triple-hormone-receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — a randomized Phase 2 trial. Nature Medicine, 30, 2037-2048. DOI: 10.1038/s41591-024-03018-2

7. Finan, B., Yang, B., Ottaway, N., et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine, 21(1), 27-36. DOI: 10.1038/nm.3761